{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:12:50Z","timestamp":1760904770506,"version":"build-2065373602"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.critrevonc.2020.102897","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:54:51Z","timestamp":1581594891000},"page":"102897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma"],"prefix":"10.1016","volume":"148","author":[{"given":"Justin H.","family":"Reid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard L.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-4733","authenticated-orcid":false,"given":"Victoria R.","family":"Nachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumana","family":"Devata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-3790","authenticated-orcid":false,"given":"Anthony J.","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.critrevonc.2020.102897_bib0005","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.18.01830","article-title":"A 73% price reduction does not indisputably justify routine application of brentuximab vedotin as first-line treatment of Hodgkin lymphoma","volume":"37","author":"Adams","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2020.102897_bib0010","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin\u2019s lymphoma: a retrospective, European, multicenter, cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.102897_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju231","article-title":"Risk of premature menopause after treatment for Hodgkin\u2019s lymphoma","volume":"106","author":"Barr","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2020.102897_bib0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"27","key":"10.1016\/j.critrevonc.2020.102897_bib0025","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.102897_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007941.pub2","article-title":"Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma","author":"Bauer","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"30","key":"10.1016\/j.critrevonc.2020.102897_bib0035","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2005.08.138","volume":"23","author":"Behringer","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102897_bib0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.15652","article-title":"The treatment of older Hodgkin lymphoma patients","volume":"184","author":"B\u00f6ll","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102897_bib0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin\u2019s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.102897_bib0050","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2141.2000.02197.x","article-title":"Historical review of Hodgkin\u2019s disease","volume":"110","author":"Bonnadonna","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"32","key":"10.1016\/j.critrevonc.2020.102897_bib0055","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"10114","key":"10.1016\/j.critrevonc.2020.102897_bib0060","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.critrevonc.2020.102897_bib0065","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJM200205023461821","article-title":"Long-term follow-up of Hodgkin\u2019s disease trial","volume":"346","author":"Canellos","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2020.102897_bib0070","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2020.102897_bib0075","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1056\/NEJMc0906731","article-title":"Long-term follow-up of survival in Hodgkin\u2019s lymphoma","volume":"361","author":"Cannellos","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2020.102897_bib0080","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score \u2265 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial","volume":"34","author":"Carde","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.102897_bib0085","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.102897_bib0090","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.critrevonc.2020.102897_bib0095","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"For the KEYNOTE-087 Investigators. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2020.102897_bib0100","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0105","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S). (2016 January 22 -). HD21 for advanced stages. Identified NCT02661503. Accessed July 11, 2019 from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02661503."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0110","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). (2019 April 9 -). Immunotherapy (nivolumab or brentuximab vedotin) plus combination chemotherapy in treating patients with newly diagnosed stage III-IV classic Hodgkin lymphoma. Identifier NCT03907488. Accessed July 11, 2019 from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03907488?cond=hodgkins+lymphoma&phase=2&draw=4&rank=25."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.102897_bib0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"ECHELON-1 study group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0120","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/blood-2018-99-118828","article-title":"Brentuximab vedotin plus chemotherapy in patients with advanced-stage classical Hodgkin lymphoma (cHL): evaluation of modified progression-free survival (mPFS) and traditional PFS in the phase 3 ECHELON-1 study","volume":"132","author":"Connors","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102897_bib0125","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3181\/00379727-120-30590","article-title":"Monoamine oxidase inhibition by a new carcinostatic agent, N-isopropyl-a (2-methyl-hydrazine)-p-toluamide (MIH)","volume":"120","author":"Devita","year":"1965","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.102897_bib0130","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin\u2019s disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.102897_bib0135","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.13634","article-title":"Evaluation of the International Prognostic Score (IPS-7) and a simpler prognostic score (IPS-3) for advanced Hodgkin lymphoma in the modern era","volume":"171","author":"Diefenbach","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.102897_bib0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1008294312741","article-title":"BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin\u2019s disease.THe German Hodgkin\u2019s Lymphoma Study Group","volume":"8","author":"Diehl","year":"1997","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2020.102897_bib0145","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"German Hodgkin\u2019s Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102897_bib0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1470-2045(03)01320-2","article-title":"Part II: Hodgkin\u2019s lymphoma--diagnosis and treatment","volume":"5","author":"Diehl","year":"2004","journal-title":"Lancet Oncol."},{"issue":"5347","key":"10.1016\/j.critrevonc.2020.102897_bib0155","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1136\/bmj.1.5347.1704","article-title":"Cure of Hodgkin\u2019s disease","volume":"1","author":"Easson","year":"1963","journal-title":"Br. Med. J."},{"issue":"9828","key":"10.1016\/j.critrevonc.2020.102897_bib0160","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.102897_bib0165","first-page":"203","article-title":"Steroids: pharmacology, complications, and practice delivery issues","volume":"14","author":"Ericson-Neilsen","year":"2014","journal-title":"Ochsner J."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.102897_bib0170","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2007.06598.x","article-title":"G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis","volume":"137","author":"Evens","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.102897_bib0175","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.102897_bib0180","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1016\/S1470-2045(13)70483-2","article-title":"BEACOPP or no BEACOPP?","volume":"14","author":"Federico","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0185","first-page":"1","article-title":"Patient-reported survivorship care practices and late effects after treatment of Hodgkin and non-Hodgkin lymphoma","volume":"2","author":"Frick","year":"2018","journal-title":"Clin. Cancer Inform."},{"issue":"24","key":"10.1016\/j.critrevonc.2020.102897_bib0190","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.102897_bib0195","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.102897_bib0200","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3324\/haematol.2011.045856","article-title":"Management of fertility in patients treated for Hodgkin\u2019s lymphoma","volume":"96","author":"Harel","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.critrevonc.2020.102897_bib0205","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 4","key":"10.1016\/j.critrevonc.2020.102897_bib0210","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/annonc\/7.suppl_4.S95","article-title":"Rationale for dose escalation of first line chemotherapy in advanced Hodgkin\u2019s disease","volume":"7","author":"Hasenclever","year":"1996","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.102897_bib0215","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<2020::AID-CNCR25>3.0.CO;2-Y","article-title":"Irreversible gonadal damage in male survivors of pediatric Hodgkin\u2019s disease","volume":"78","author":"Heikens","year":"1996","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2020.102897_bib0220","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102897_bib0225","first-page":"69","article-title":"On some morbid appearances of the absorbent glands and spleen","volume":"17","author":"Hodgkin","year":"1832","journal-title":"Med. Chirugical Trans."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102897_bib0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.802","article-title":"Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy","volume":"25","author":"Hodgson","year":"2007","journal-title":"Hematol. Oncol."},{"issue":"33","key":"10.1016\/j.critrevonc.2020.102897_bib0235","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.18.00122","article-title":"Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma","volume":"36","author":"Huntington","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.102897_bib0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1148\/radiol.2015142088","article-title":"Imaging for staging and response assessment in lymphoma","volume":"276","author":"Johnson","year":"2015","journal-title":"Radiology"},{"issue":"25","key":"10.1016\/j.critrevonc.2020.102897_bib0245","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0250","first-page":"35","article-title":"Quality of life and fertility in Hodgkin disease patients treated with escalated BEACOPP","volume":"94","author":"Jurczak","year":"2009","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.critrevonc.2020.102897_bib0255","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2018-05-852129","article-title":"Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma","volume":"132","author":"Kobe","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102897_bib0260","first-page":"1","article-title":"German Hodgkin Study Group. Survivors\u2019 perspective on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group","volume":"3","author":"Kreissl","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.102897_bib0265","series-title":"Hematology: Basic Principles and Practice","article-title":"Origin of Hodgkin lymphoma","author":"K\u00fcppers","year":"2018"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102897_bib0270","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.critrevonc.2020.102897_bib0275","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2017-09-772640","article-title":"Optimizing therapy in advanced-stage Hodgkin lymphoma","volume":"131","author":"Lim","year":"2018","journal-title":"Blood"},{"issue":"Suppl 5","key":"10.1016\/j.critrevonc.2020.102897_bib0280","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/annonc\/9.suppl_5.S73","article-title":"Model based development of the BEACOPP regimen for advanced stage disease","volume":"9","author":"Loeffler","year":"1998","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.102897_bib0285","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.1986.4.9.1295","article-title":"Twenty years of MOPP therapy for Hodgkin\u2019s disease","volume":"4","author":"Longo","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0290","article-title":"Risk-adapted treatment of advanced Hodgkin lymphoma with PET-CT","volume":"36","author":"Lynch","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"8","key":"10.1016\/j.critrevonc.2020.102897_bib0295","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"27","key":"10.1016\/j.critrevonc.2020.102897_bib0300","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International Prognostic Score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.102897_bib0305","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u2265 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0310","first-page":"1258","article-title":"Intensive combination chemotherapy and X-irradiation in Hodgkin\u2019s disease","volume":"27","author":"Moxley","year":"1967","journal-title":"Cancer Res."},{"year":"2019","series-title":"Hodkgin Lymphoma","author":"National Comprehensive Cancer Network","key":"10.1016\/j.critrevonc.2020.102897_bib0315"},{"key":"10.1016\/j.critrevonc.2020.102897_bib0320","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2014-05-579193","article-title":"Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects","volume":"124","author":"Ng","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2020.102897_bib0325","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"S2","key":"10.1016\/j.critrevonc.2020.102897_bib0330","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hon.106_2629","article-title":"Cost-effectiveness and cost-utility analysis of multiple treatment strategies using ABVD and\/or BEACOPP in the treatment of advanced-stage Hodgkin lymphoma","volume":"37","author":"Prica","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0335","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jama.1902.62480030024001h","article-title":"Cases of sarcoma and of Hodgkin\u2019s disease treated by exposures to X-rays: a preliminary report","volume":"98","author":"Pusey","year":"1902","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.critrevonc.2020.102897_bib0340","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0345","first-page":"133","article-title":"On the pathological changes in Hodgkin\u2019s disease, with especial reference to its relation to tuberculosis","volume":"10","author":"Reed","year":"1902","journal-title":"Johns Hopkins Hospital Reports"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.102897_bib0350","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1470-2045(19)30081-6","article-title":"PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma","volume":"20","author":"Reid","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0355","first-page":"27","article-title":"The effect of nitrogen mustard and maintenance chlorambucil in the treatment of advanced Hodgkin\u2019s disease","volume":"27","author":"Scott","year":"1963","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0360","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Hodgkin lymphoma. https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html. Accessed April 1st, 2019."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.102897_bib0365","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.102897_bib0370","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1078155215574294","article-title":"The role of screening and monitoring for bleomycin pulmonary toxicity","volume":"22","author":"Shippee","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.102897_bib0375","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2007-02-073544","article-title":"Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)","volume":"111","author":"Sieniawski","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102897_bib0380","article-title":"Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0385","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with Stage III\/IV Hodgkin lymphoma [published online ahead of print July 22]","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2020.102897_bib0390","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood.V128.22.3002.3002","article-title":"Patterns of clinical presentation in patients with classical Hodgkin lymphoma and impact on prognosis","volume":"128","author":"Strelec","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.102897_bib0395","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1182\/blood.V92.12.4560","article-title":"Moderate dose escalation for advanced stage Hodgkin\u2019s disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin\u2019s Lymphoma Study Group","volume":"92","author":"Tesch","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102897_bib0400","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hon.2437_53","article-title":"Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: longer follow-up confirms efficacy of de-escalation after a negative interim PET scan (CRUK\/07\/033)","volume":"35","author":"Trotman","year":"2017","journal-title":"Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.102897_bib0405","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.1989.7.12.1776","article-title":"Dose intensity of MOPP chemotherapy and survival in Hodgkin\u2019s disease","volume":"7","author":"van Rijswijk","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.102897_bib0410","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linformi. ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.102897_bib0415","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2020.102897_bib0420","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1016\/S2352-3026(18)30140-6","article-title":"German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin\u2019s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials","volume":"5","author":"von Tresckow","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2020.102897_bib0425","unstructured":"World Cancer Research Fund. Worldwide cancer data: global cancer statistics for the most common cancers. https:\/\/www.wcrf.org\/dietandcancer\/cancer-trends\/worldwide-cancer-data. Accessed April 1st, 2019."},{"issue":"13","key":"10.1016\/j.critrevonc.2020.102897_bib0430","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820300354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820300354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:32:43Z","timestamp":1760902363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820300354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":86,"alternative-id":["S1040842820300354"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102897","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102897"}}